Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.
SMI 12’165 -0.4%  SPI 16’676 -0.3%  Dow 42’221 -0.5%  DAX 23’639 0.3%  Euro 0.9403 0.2%  EStoxx50 5’416 0.4%  Gold 3’252 0.5%  Bitcoin 87’718 0.9%  Dollar 0.8413 -0.6%  Öl 66.7 2.7% 
Beliebte Suchen
SMI Öl Schweizer Franken - Euro Bitcoin Goldpreis
Top News
Ausblick: Daimler Truck legt Zahlen zum jüngsten Quartal vor
Börsenexperte warnt: Steht der Aktienmarkt vor der nächsten Korrektur?
Ausblick: Brenntag SE stellt das Zahlenwerk zum vergangenen Quartal vor
Flughafen Zürich-Aktie: Erneut Passagieranstieg im April
Microsoft streicht mehrere Tausend Stellen - Microsoft-Aktie leichter
Suche...
Plus500 Depot
Kurse + Charts + Realtime News + Analysen Fundamental Unternehmen zugeh. Wertpapiere Aktion
Kurs + Chart Chart (gross) News + Adhoc Bilanz/GuV Termine Strukturierte Produkte Portfolio
Times + Sales Chartvergleich Analysen Schätzungen Profil Trading-Depot Watchlist
Börsenplätze Realtime Push Kursziele Dividende/GV
Orderbuch Analysen
Historisch
Kurse + Charts + Realtime

Kurs + Chart

Chart (gross)

Times + Sales

Chartvergleich

Börsenplätze

Realtime Push

Orderbuch

Historisch

News + Analysen

News + Adhoc

Analysen

Kursziele

Fundamental

Bilanz/GuV

Schätzungen

Dividende/GV

Analysen

Unternehmen

Termine

Profil

zugeh. Wertpapiere

Strukturierte Produkte

Trading-Depot

Aktion

Portfolio

Watchlist

13.05.2025 07:00:15

EQS-News: Springer Nature reports strong start to 2025

Springer Nature
19.76 EUR 7.74%
Kaufen Verkaufen

EQS-News: Springer Nature AG & Co. KGaA / Key word(s): Quarterly / Interim Statement/Quarterly / Interim Statement
Springer Nature reports strong start to 2025

13.05.2025 / 07:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

 

PRESS RELEASE
 

Springer Nature reports strong start to 2025
  • Revenue grew by 6% and adjusted operating profit (AOP) increased by 11% in the first three months of 2025; both on an underlying[1] basis 
  • Research was the key growth driver, led by strong performance in Full Open Access (FOA)
  • Strategic priorities on track: Solid progress in Open Access (OA) and AI initiatives
  • Full-year 2025 guidance now includes an AOP range; results expected in the upper half of the revenue and AOP ranges

Berlin, 13 May 2025

Springer Nature, a leading global publisher of research, today released strong results for the first three months of its financial year 2025. Revenue grew to €450 million, representing a 6% increase on an underlying1 basis compared to the same period last year. Adjusted operating profit reached €108 million, equating to underlying1 growth of 11%, which was mainly the result of positive revenue development during the quarter.

Frank Vrancken Peeters, CEO of Springer Nature, said: “These strong first-quarter results reflect the fact that we continue to successfully deliver on our strategy to grow sustainably and to add value to our communities. I am particularly pleased with the growth in the amount of content we are making immediately open for all to use, while continuing to invest in people and technology, and to safeguard research integrity.”

In the reported period, Research was a key contributor to Springer Nature's performance seeing an underlying1 revenue growth of 7%. This was led by a strong performance in open access (OA) including an increase of about 25%[2] on prior year in published articles in its full open access (FOA) journals. Fourteen new transformative agreements were also agreed, taking the total to 80, further driving the global OA transition. In addition, around 90% of contract renewals for 2025 have already been completed.

Two new Nature review journals (Nature Reviews Clean Technology and Nature Reviews Biodiversity) were launched, supporting researchers in new emerging fields.

Springer Nature continued to invest in technology to transform the publishing process. Snapp, the company’s proprietary article processing platform, saw submission growth of 80% in the first quarter, which includes newly migrated journals. Springer Nature also launched new AI tools to help ensure research integrity.

Health generated revenue of €41 million, with 4% underlying[3] revenue growth in the first three months of 2025. Growth was driven by strong demand in the international pharma business and BSL in the Netherlands. Education revenue was broadly flat on an underlying3 basis at €54 million in the first three months, with negative revenue phasing in Southern Africa balancing strong performance in the Southern hemisphere.

Springer Nature retained its focus on growing responsibly – reducing its impact on the planet, maintaining strong customer satisfaction and investing in creating a great place to work. In January, the company was once again recognised as a leading employer in Germany, the UK and the US by the LEADING EMPLOYERS study.

Free cash flow increased to €158 million from €142.5 in the same period last year. This was mainly the results of operational improvement as well as lower interest payments. Consequently, Springer Nature further reduced its financial leverage ratio to 2.0x net debt/EBITDA from 2.3x at the end of 2024.

Alexandra Dambeck, the company’s CFO, said: “We have succeeded in further improving both our operating performance and financial leverage, continuing our strong trajectory from last year. Therefore, we are confident in refining our 2025 guidance and expect to be in the upper half of the ranges.”

Springer Nature's guidance is based on the underlying3 performance and constant foreign exchange rates. The company has refined its full-year 2025 guidance and now expects results to be in the upper half of the previously communicated revenue range of €1,885 million to €1,935 million. Springer Nature has also introduced an adjusted operating profit range of €523 million to €546 million, with expectations likewise toward the upper half of this range. The company’s mid-term outlook remains unchanged.
 

Springer Nature financial KPI Q1 2025

Key performance indicators
in € million 3M 2025 3M 2024 Change Underlying
change
Revenue 450.3 429.2 4.9% 5.6%
Adjusted operating profit 107.9 98.8 9.2% 10.5%
Adjusted operating profit margin 24.0% 23.0% 93bps 107bps
Free cash flow 158.0 142.5 15.5  

 

Revenue
in € million 3M 2025 3M 2024 Change Underlying
change
Group 450.3 429.2 4.9% 5.6%
Segments
Researcha,b		 354.9 331.7 7.0% 6.7%
Health 41.1 39.2 4.9% 4.3%
Educationc 54.4 58.8 (7.4%) (0.7%)
Consolidation (0.3) (0.6)    
a      American Journal Experts (AJE), the language-editing business, sold in February 2024, contributed revenue of €3.1 million.
b      The Professional segment was integrated in the Research segment as at 1 January 2025. The presentation of the previous year has been adjusted accordingly.
c      Education reported revenue and AOP in Q1 2024 have been amended for a hyperinflation related accounting adjustment in Zimbabwe. The adjustment did not have an effect on H1 2024, or the FY 2024 reported figures of the segment or the Group.

Adjusted operating profit
in € million 3M 2025 3M 2024 Change
Underlying
Change
Group 107.9 98.8 9.2% 10.5%
Segments
Researcha		 99.5 90.2 10.3% 7.7%
Health 4.5 3.7 22.8% 21.9%
Educationb 3.7 4.9 (23.5%) >200.0%
Consolidation 0.1 0.0    
a      The Professional segment was integrated in the Research segment as at 1 January 2025. The presentation of the previous year has been adjusted accordingly.
b      Education reported revenue and AOP in Q1 2024 have been amended for a hyperinflation related accounting adjustment in Zimbabwe. The adjustment did not have an effect on H1 2024, or the FY 2024 reported figures of the segment or the Group.

Notes relating to forward-looking statements
This document contains statements about the future business development and strategic direction of the company. The forward-looking statements are based on management's current expectations and assumptions. They are subject to certain risks and fluctuations as described in other publications, in particular in the risk and opportunities management section of the combined management report. If these expectations and assumptions do not apply or if unforeseen risks arise, the actual course of business may differ significantly from the expected developments. We therefore assume no liability for the accuracy of these forecasts.

About Springer Nature
Springer Nature is one of the leading publishers of research in the world. We publish the largest number of journals and books and are a pioneer in open research. Through our leading brands, trusted for more than 180 years, we provide technology-enabled products, platforms and services that help researchers to uncover new ideas and share their discoveries, health professionals to stay at the forefront of medical science, and educators to advance learning. We are proud to be part of progress, working together with the communities we serve to share knowledge and bring greater understanding to the world. For more information, please visit about.springernature.com and @SpringerNature.
 
Contact

Cornelius Rahn | Springer Nature | Communications and Corporate Affairs
tel +49 151 1563 7515 | cornelius.rahn@springernature.com
 

[1] Underlying changes excludes effects from year-on-year changes in foreign currencies and portfolio.

[2] Excluding Cureus.

[3] Underlying changes excludes effects from year-on-year changes in foreign currencies and portfolio.


13.05.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
Language: English
Company: Springer Nature AG & Co. KGaA
Heidelberger Platz 3
14197 Berlin
Germany
Phone: +49 (0)30 - 82787 - 0
E-mail: ir@springernature.com
Internet: www.springernature.com
ISIN: DE000SPG1003
WKN: SPG100
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange (Vienna MTF)
EQS News ID: 2135406

 
End of News EQS News Service

2135406  13.05.2025 CET/CEST

Nachrichten zu Springer Nature

  • Relevant
  • Alle
  • vom Unternehmen
  • ?
mehr Nachrichten

Analysen zu Springer Nature

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
12:31 Springer Nature Overweight JP Morgan Chase & Co.
30.04.25 Springer Nature Overweight Barclays Capital
09.04.25 Springer Nature Buy Goldman Sachs Group Inc.
26.03.25 Springer Nature Buy Goldman Sachs Group Inc.
19.03.25 Springer Nature Overweight JP Morgan Chase & Co.
mehr Analysen
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

Die David-Schere erklärt: 5 Kennzahlen für starke Aktien – am Beispiel von SAP

Seit Anfang 2023 präsentieren der Investment-Stratege François Bloch und Börsenexperte David Kunz jeweils drei sorgfältig ausgewählte Aktien im BX Morningcall.
Eine Begrifflichkeit, die im Zusammenhang mit der Titelauswahl immer wieder fällt, ist die «David-Schere».

Was verbirgt sich hinter der #David-Schere? In diesem Video erklärt François Bloch, warum diese Methode zur #Aktienbewertung eine echte Geheimwaffe ist – und was sie so treffsicher macht.
Gemeinsam mit David Kunz nehmen wir den Technologiegiganten #SAP unter die Lupe und zeigen anhand von fünf Kennzahlen, warum diese Aktie derzeit besonders spannend ist.:

✅ Umsatz
✅ EBIT
✅ EBIT Marge
✅ Dividende
✅ Gewinn pro Aktie

Pünktlich zum Börsenstart diskutieren Investment-Stratege François Bloch und Börsen-Experte David Kunz oder Olivia Hähnel über ausgewählte Top-Aktienwerte aus dem BX Musterportfolio.

👉🏽 https://bxplus.ch/bx-musterportfolio/

Die David-Schere erklärt: 5 Kennzahlen für starke Aktien – am Beispiel von SAP

Inside Trading & Investment

17:45 Logo WHS BRICS-Chancen: Neue Währung und neues Finanzsystem - Kostenloses Webinar heute um 19:00 Uhr
14:41 Adecco – mit KI und Flexibilität in die Zukunft
12:10 Julius Bär: 8.50% p.a. JB Barrier Reverse Convertible (55%) auf Societe Generale SA
10:28 Raiffeisen: Produkte im Fokus - 10.00% p.a. Multi Barrier Reverse Convertible auf Adecco, Lonza, UBS
09:34 SG-Marktüberblick: 13.05.2025
08:21 Pharma-Schwergewichte ziehen Kopf aus der Schlinge
06:05 UBS Logo UBS KeyInvest: SMI – Trendlinie im Fokus
07.05.25 Die David-Schere erklärt: 5 Kennzahlen für starke Aktien – am Beispiel von SAP
02.12.24 Jetzt ohne Trading-Gebühren regelmässig mit Vanguard ETFs sparen.
mehr

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 12’674.36 17.89 BKYSTU
Short 12’937.19 13.50 SS4MTU
Short 13’407.31 8.78 B02SIU
SMI-Kurs: 12’165.27 13.05.2025 17:31:28
Long 11’727.64 19.68 BX7SBU
Long 11’431.60 13.19 BXGS2U
Long 10’984.40 8.85 BAOSEU
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com

Meistgelesene Nachrichten

Diese Aktien empfehlen die Experten zum Kauf
DocMorris Aktie News: Bären lasten am Dienstagnachmittag auf DocMorris
Nach turbulentem Monat am Aktienmarkt: Das rät Warren Buffett jetzt
Nach US-Inflationsdaten: SMI schliesst im Minus -- DAX geht fester aus dem Handel -- Hang Seng letztlich verlustreich
Positive Signale im Handelsstreit: SMI letztlich im Plus -- DAX schliesst nach neuem Rekord höher -- Asiens Börsen beenden Handel freundlich
Bayer-Aktie zieht an: Bayer startet besser als erwartet ins Jahr - Pharma-Sparte glänzt
Rheinmetall-Aktie: Hauck Aufhäuser Lampe Privatbank AG vergibt Bewertung
"Sell in May": Warum Experten momentan davon abraten, die Börsenweisheit zu befolgen
ABB-Aktie höher: ABB prüft angeblich auch Verkauf der Robotik-Sparte als Option
NVIDIA-Aktie im Visier: Neuer US-Gesetzentwurf zielt auf Chip-Schmuggel nach China

Top-Rankings

KW 19: Das waren die Tops und Flops der SMI-Aktien in der vergangenen Woche
Der SMI stand in der vergangenen Woche einmal mehr im Bann von Konjunktur und Politik. So bewegt ...
Bildquelle: Maksim Kabakou / Shutterstock.com
KW 19: Das waren die Gewinner und Verlierer im DAX
Im Laufe der Woche kam es am deutschen Aktienmarkt zu Ausschlägen. So entwickelten sich die Einz ...
Bildquelle: Maksim Kabakou / Shutterstock.com
Die Performance der Kryptowährungen in KW 19: Das hat sich bei Bitcoin, Ether & Co. getan
Am Kryptomarkt bewegten sich einige Werte in der vergangenen Handelswoche stark. Das sind die Ge ...
Bildquelle: Wit Olszewski / Shutterstock.com
Alle Top-Rankings. Klicken Sie hier.

finanzen.net News

Datum Titel
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
{{ARTIKEL.NEWS.BODY.TITEL}}